Dianthus Therapeutics, Inc.
General ticker "DNTH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0B (TTM average)
Dianthus Therapeutics, Inc. follows the US Stock Market performance with the rate: 49.8%.
Estimated limits based on current volatility of 3.7%: low 77.43$, high 83.39$
Factors to consider:
- Total employees count: 53 as of 2023
- Current price 41.1% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [25.44$, 58.05$]
- 2026-12-31 to 2027-12-31 estimated range: [17.21$, 41.83$]
Financial Metrics affecting the DNTH estimates:
- Negative: with PPE of -10.3 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 92.93 > 64.29
- Positive: Inventory ratio change, % of -29.71 <= -0.75
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -14.17 < Investing cash flow per share per price, % of -7.72
Short-term DNTH quotes
Long-term DNTH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.83MM | $6.24MM | $2.04MM |
| Operating Expenses | $51.00MM | $108.10MM | $179.97MM |
| Operating Income | $-48.17MM | $-101.86MM | $-177.93MM |
| Non-Operating Income | $4.62MM | $16.89MM | $15.60MM |
| R&D Expense | $32.84MM | $83.11MM | $145.64MM |
| Income(Loss) | $-43.55MM | $-84.97MM | $-162.34MM |
| Net Income(Loss)* | $-43.55MM | $-84.97MM | $-162.34MM |
| Stockholders Equity | $168.87MM | $352.48MM | $493.40MM |
| Assets | $179.41MM | $374.01MM | $530.92MM |
| Operating Cash Flow | $-36.86MM | $-78.18MM | $-129.06MM |
| Capital expenditure | $0.11MM | $0.10MM | $0.21MM |
| Investing Cash Flow | $20.25MM | $-286.81MM | $-122.83MM |
| Financing Cash Flow | $133.57MM | $255.62MM | $280.12MM |
| Earnings Per Share** | $-8.45 | $-2.55 | $-4.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.